By Michael Erman NEW YORK, Sept 18 (Reuters) - The US is working on rules for pharmaceutical companies investing in China ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

The U.S. is drafting rules for biopharma firms investing in China that would likely maintain their ability to ink most licensing deals for Chinese drugs. Read more here.

The US Treasury Department is drafting rules to allow most pharma licensing deals with China while restricting pathogen and ...

A new five-year biotech plan has been released by the Chinese government, revealing ambitious goals such as achieving five blockbuster medicines on the global markets in that time.

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Dublin, April 15, 2025 (GLOBE NEWSWIRE) -- The "China Pharmaceutical Directory 2025" has been added to ResearchAndMarkets.com's offering. The Chinese pharmaceutical industry has increased with high ...

Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world's pharma companies shore up their pipelines in anticipation of an approaching patent ...

Big Pharma companies have often talked about the major opportunities that await in China. But as price cuts play out and internal priorities shift, multinational companies are reworking their business ...

The billionaire chairman of one of China’s largest service providers to its growing pharmaceutical and medical device ...

Thanks to its scientific skills base, growing prowess in AI and a policy environment that supports rapid clinical trials, China has become one of the world’s leading markets for pharmaceutical ...